Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72:524–41. https://doi.org/10.3322/caac.21754.

Article  PubMed  Google Scholar 

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52. https://doi.org/10.1016/s0140-6736(15)61074-1

Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383:2557–70. https://doi.org/10.1056/NEJMra1307118.

Article  PubMed  CAS  Google Scholar 

Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36. https://doi.org/10.1056/NEJMoa1607303.

Article  PubMed  CAS  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46. https://doi.org/10.1200/jco.2017.75.6155.

Article  PubMed  CAS  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–48. https://doi.org/10.1056/NEJMoa1609709.

Article  PubMed  CAS  Google Scholar 

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15. https://doi.org/10.1016/s1470-2045(18)30292-4.

Article  PubMed  CAS  Google Scholar 

Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–13. https://doi.org/10.1038/nature10762.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res. 2008;14:1938–46. https://doi.org/10.1158/1078-0432.Ccr-07-4082.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cummings MC, Simpson PT, Reid LE, Jayanthan J, Skerman J, Song S, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232:23–31. https://doi.org/10.1002/path.4288.

Article  PubMed  CAS  Google Scholar 

Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24:101–8. https://doi.org/10.1093/annonc/mds248.

Article  PubMed  CAS  Google Scholar 

Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, et al. Diagnostic accuracy and safety of 16α-[(18)F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol. 2019;20:546–55. https://doi.org/10.1016/s1470-2045(18)30936-7.

Article  PubMed  CAS  Google Scholar 

van Geel JJL, Boers J, Elias SG, Glaudemans A, de Vries EFJ, Hospers GAP, et al. Clinical validity of 16α-[(18)F]Fluoro-17β-Estradiol positron emission tomography/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer. J Clin Oncol. 2022;40:3642–52. https://doi.org/10.1200/jco.22.00400.

Article  PubMed  Google Scholar 

Ulaner GA. 16α-18F-fluoro-17β-Fluoroestradiol (FES): clinical applications for patients with breast cancer. Semin Nucl Med. 2022;52:574–83. https://doi.org/10.1053/j.semnuclmed.2022.03.002.

Article  PubMed  Google Scholar 

Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med. 2011;52:1541–9. https://doi.org/10.2967/jnumed.111.091439.

Article  PubMed  CAS  Google Scholar 

Nienhuis HH, van Kruchten M, Elias SG, Glaudemans A, de Vries EFJ, Bongaerts AHH, et al. (18)F-Fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients. J Nucl Med. 2018;59:1212–8. https://doi.org/10.2967/jnumed.117.198846.

Article  PubMed  CAS  Google Scholar 

Liu C, Hu S, Xu X, Zhang Y, Wang B, Song S, et al. Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment. Breast Cancer Res. 2022;24:57. https://doi.org/10.1186/s13058-022-01555-7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Boers J, Venema CM, de Vries EFJ, Glaudemans A, Kwee TC, Schuuring E, et al. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer. 2020;126:11–20. https://doi.org/10.1016/j.ejca.2019.10.024.

Article  PubMed  CAS  Google Scholar 

Gennari A, Brain E, De Censi A, Nanni O, Wuerstlein R, Frassoldati A, et al. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with (18)F-fluoroestradiol ((18)F-FES) CT/PET. Ann Oncol. 2024;35:549–58. https://doi.org/10.1016/j.annonc.2024.02.007.

Article  PubMed  CAS  Google Scholar 

Ryu J, Hyung J, Han S, Jeong JH, Lee SB, Yoo TR, et al. Impact of (18)F-FES PET/CT on clinical decisions in the management of recurrent or metastatic breast cancer. J Nucl Med. 2024;65:1689–94. https://doi.org/10.2967/jnumed.124.267913.

Article  PubMed  Google Scholar 

Oh SJ, Chi DY, Mosdzianowski C, Kil HS, Ryu JS, Moon DH. The automatic production of 16alpha-[18F]fluoroestradiol using a conventional [18F]FDG module with a disposable cassette system. Appl Radiat Isot. 2007;65:676–81. https://doi.org/10.1016/j.apradiso.2006.06.016.

Article  PubMed  CAS  Google Scholar 

Venema CM, Apollonio G, Hospers GA, Schröder CP, Dierckx RA, de Vries EF, et al. Recommendations and technical aspects of 16α-[18F]Fluoro-17β-estradiol PET to image the estrogen receptor in vivo: the Groningen experience. Clin Nucl Med. 2016;41:844–51. https://doi.org/10.1097/rlu.0000000000001347.

Article  PubMed  Google Scholar 

Chae SY, Kim SB, Ahn SH, Kim HO, Yoon DH, Ahn JH, et al. A Randomized feasibility study of (18)F-Fluoroestradiol PET to predict pathologic response to neoadjuvant therapy in estrogen receptor-rich postmenopausal breast cancer. J Nucl Med. 2017;58:563–8. https://doi.org/10.2967/jnumed.116.178368.

Article  PubMed  CAS  Google Scholar 

Mankoff D, Balogová S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, et al. Summary: SNMMI Procedure Standard/EANM Practice Guideline for estrogen receptor imaging of patients with breast cancer using 16α-[(18)F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024;65:221–3. https://doi.org/10.2967/jnumed.123.266938.

Article  PubMed  CAS  Google Scholar 

Breast cancer (Version 1.2024). NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 6 Mar 2024.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105–22. https://doi.org/10.1200/jco.2018.77.8738.

Article  PubMed  CAS  Google Scholar 

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49. https://doi.org/10.1016/j.annonc.2020.09.010.

Article  PubMed  CAS  Google Scholar 

Ulaner GA, Mankoff DA, Clark AS, Fowler AM, Linden HM, Peterson LM, et al. Summary: appropriate use criteria for estrogen receptor-targeted PET imaging with 16α-(18)F-Fluoro-17β-Fluoroestradiol. J Nucl Med. 2023;64:351–4. https://doi.org/10.2967/jnumed.123.265420.

Article  PubMed  CAS  Google Scholar 

Ulaner GA, Jhaveri K, Chandarlapaty S, Hat